Volume | 548 |
|
|||||
News | - | ||||||
Day High | 31.83 | Low High |
|||||
Day Low | 31.62 |
Company Name | Etf Ticker Symbol | Market | Type |
---|---|---|---|
ALPS Medical Breakthroughs ETF | SBIO | AMEX | Exchange Traded Fund |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
31.62 | 31.62 | 31.83 | 31.53 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
16 | 548 | 31.68 | 17,362 | - | 23.21 - 38.80 |
Last Trade Time | Type | Quantity | Etf Price | Currency |
---|---|---|---|---|
09:57:11 | 2 | 31.865 | USD |
ALPS Medical Breakthroughs ETF Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
100.11M | 3.18M | - | 163k | -17.09M | -5.38 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
News ALPS Medical Breakthroug...
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
SBIO Historical
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 31.73 | 32.71 | 31.00 | 31.71 | 21,280 | 0.10 | 0.32% |
1 Month | 35.66 | 35.66 | 31.00 | 32.87 | 12,064 | -3.83 | -10.74% |
3 Months | 33.59 | 38.80 | 31.00 | 35.06 | 13,733 | -1.76 | -5.24% |
6 Months | 24.17 | 38.80 | 23.21 | 32.24 | 12,065 | 7.66 | 31.69% |
1 Year | 29.86 | 38.80 | 23.21 | 31.14 | 10,345 | 1.97 | 6.60% |
3 Years | 48.79 | 50.98 | 23.21 | 34.84 | 17,146 | -16.96 | -34.76% |
5 Years | 34.44 | 64.04 | 23.21 | 38.49 | 26,631 | -2.61 | -7.58% |
The Fund seeks investment results that correspond before fees and expenses generally to the performance of its underlying index the Poliwogg Medical Breakthroughs ndexSM ticker symbol PMBI the Underlying Index. The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials. |